Johnson & Johnson Raises 2026 Guidance After Q2 Beat

Earnings
โดย Zacks Investment Research·US·Read original
Summary · why it matters

Johnson & Johnson raised its full-year 2026 guidance after second-quarter earnings and sales beat estimates. Adjusted earnings per share came in at $2.90, above the Zacks Consensus Estimate of $2.84, while sales of $25.3 billion edged past the $25.1 billion consensus. The company now expects 2026 reported sales of $100.8 billion to $101.4 billion, up from $100.3 billion to $101.3 billion, and adjusted EPS of $11.60 to $11.75, up from $11.45 to $11.65. Innovative Medicine sales rose 7.8% to $16.38 billion, driven by Darzalex, Tremfya, and new drugs like Carvykti, while MedTech sales increased 4.5% to $8.93 billion. Shares have added about 4.8% since the last earnings report, outperforming the S&P 500.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
© 2026 MarketDXNews